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Interference in analysis, in particular in immunoassay,
remains a perpetual headache for the laboratory and po-
tential pitfall for the clinician. Interference has been
documented for all types of immunoassay and includes
analyte independent interferences (pre-analytical or
analytical) and analyte dependent interferences [1]. Inter-
ference from drugs is fortunately rare but does occur.
Troponin measurement now defines myocardial
infarction [2]. Treatment strategies for patients with non-ST
elevation myocardial infarction (NSTEMI) are predicated by
troponin measurement [3]. The development of high sensi-
tivity troponin assays, defined as thosewith imprecision less
than 10% at the 99th percentile and able to measure at least
50% of a reference population [4], has further changed the
way cardiac biomarkers are used. Rapid diagnostic algo-
rithms able to rule out NSTEMI by measurement of a single
sample on hospital admission or following serial measure-
ment over 1–2 h have been developed and extensively vali-
dated. Such strategies have been endorsed by the UK health
technology assessment programme ([5] guidance soon to be
updated) and by The European Society of Cardiology [3].
They depend on the ability to measure very low values of
troponin reliably and that repeat measurements have low
imprecision. Therewas therefore alarmwhen itwas reported
that there was a risk of false negative troponin results in





The majority of discussions following improvement in
troponin assay sensitivity and the introduction of high
sensitivity assays has been around “false positive” results.
Much of this has been ill informed, with troponin elevation
outside the spectrum of acute coronary syndromes (ACS)
being labelled as “false positive” and given labels such as
“troponinitis”. Much of this confusion is due over
requesting of troponin in patients who do not have ACS or
even suspicion of ACSwith requestsmade “just in case” [6].
Although true false positive troponin results can occur they
are very rare and have the same causes as in other immu-
noassays, although there are false positives unique to
troponin assays. Troponin elevations outside ACS indicate
myocardial injury and are associated with a worse prog-
nosis, whatever the cause [7, 8]. The main role of clinical
testing for troponin is exclusion of myocardial infarction
and of significant myocardial injury from any cause. In this
regard, high sensitivity troponin assays are clinically
excellent and this exquisite sensitivity is the basis of rule
out algorithms. No troponin elevation means an excellent
prognosis and safe discharge from hospital, with minimal
hospital stay. This is an important attribute in the times of
COVID 19. The documentation of a potential cause of false
negative results is therefore worrying.
Steptavidin-biotin based assays have the potential for
immunoassay interference. This was first documented in
1996 [9]. However the likelihood of encountering high
levels of biotin outside of specific treatment regimens was
considered unlikely [10]. Such interventions would also be
expected to be documented as part of the drug chart.
However, the current enthusiasm for biotin supplementa-
tion to improve hair and nails (with accompanying celeb-
rity endorsement) means that a large number of people are
taking biotin supplements, with a typical starting dose of
10 mg, for which there is little evidence of benefit [11].
Analytical interference has been demonstrated at the 10mg
level of supplementation [12] although the interference is
variable between assay type and formulation [13].
Is this a real problem? An earlier study from the Mayo
clinic suggested that 7.4% of patients attending the
Emergency Department (ED) had biotin concentrations
exceeding 10 μg/L [14]. This group subsequently estimated
a clinical risk of 0.8% for the ED population. There have
been other publications which have examined the rate of
biotin elevation. These have variously estimated the pro-
portion exceeding 10 μg/L as 0.8% (EDpopulation) [15] and
0.2% (routine laboratory requests) [16].
In this issue of the journal Mumma [17] and colleagues
report a novel approach to assessing the risk of biotin
interference. They combine estimation of prevalence of
significant elevation with risk modelling in two different
cohorts of patients. In the first cohort they used patients
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enrolled in a clinical study of suspected ACS andmeasured
biotin levels in residual samples. In the second cohort they
used randomly selected samples submitted for routine
analysis to a US laboratory. In both cohorts they obtain the
prevalence of an elevated biotin (defined as exceeding
20 μg/L). They then undertake a modelling exercise to
determine the likelihood that an elevated biotin would
result in misclassification of a patient with acute myocar-
dial infarction (AMI) based on misclassification at the 99th
percentile. In the second cohort they additionally attempt
tomodel the potential impact of elevated biotin resulting in
interference with a single sample rule out strategy by
lowering the troponin below the rule out decision
threshold. In the ACS population, the percentage of pa-
tients with biotin >20 μg/L was 0.13%. In the laboratory
population it was 0.74%. In the ACS population the risk of
misclassification of AMI (based on the 99th percentile) was
0.026%. For the general laboratory population the derived
risk for misclassification of AMI was 0.025% and for the
single sample rule out strategy it was 0.063%. How should
these findings be interpreted in relation to the current
literature in this field? The first problem is the prevalence of
elevated biotin. The second is the question of the assay
version, interference threshold selected, and the pharma-
cokinetics of biotin ingestion.
Biotin measurements are not standardised. In the
original Mayo clinic publication measurement was by
liquid chromatography tandem-mass spectrometry
(LC-MS/MS) [14]. This technique was also used by two of
the other groups documenting values above 10 μg/L [15,
16]. The authors have used a research immunoassay which
detects total serum biotin. The argument for this is that it
detects all biotin species including metabolites, so is more
likely to detect the levels at which interference will occur.
Although the assay is calibrated against LC-MS/MS biotin
measurements the slope of the graph is not 1.0 suggesting
under recovery, which is slightly surprising for an assay
that measures total biotin (including other forms of biotin)
rather than biotin alone.
The question of assay version, interference threshold,
and the effect of biotin ingestion is much more compli-
cated. Evaluation of the fifth generation troponin T assay
reported no interference was observed with biotin con-
centrations upto 20 μg/L [18]. In examining the impact of
biotin interference it was reported that concentrations of
15.6 μg/L or greater would generate significant interfer-
ence [13]. The choice of 20 μg/L as the interference
threshold might therefore be somewhat optimistic as it is
derived from spiking experiments. In a volunteer study,
five normal individuals ingested a supplement containing
10mg biotin per day, a commonly available dose. The post
ingestion levels of biotin detected would have been ex-
pected to generate a significant fall in measured troponin
values [19]. This study also showed the variability in dose
response between individuals following biotin ingestion.
A further complicating factor is that the spiking experi-
ments in vitromay not mimic the biological effect of biotin
ingestion (alone or as a multivitamin preparation) with
interference by biotin metabolites and other tablet con-
stituents in addition to that of biotin alone. To add a
further level of complexity, it is possible that measured
biotin levels do not necessarily reflect the value that
generates assay interference when biotin is taken as a
supplement.
What may we conclude? The differences between the
studies using LC MS/MS may represent different pop-
ulations with Americans tending to take more biotin
containing supplements. Comparing the prevalence in the
two US studies, there are different methods for biotin
measurement in different populations and a different cut-
off has been used. The risk of interference in the assay
would therefore seem to be between a pessimistic 0.8%
and an optimistic 0.063–0.025% and is driven by the es-
timate of the percentage above the interference threshold.
Based on UK figures for chest pain admissions this would
mean between 3,600 and 28 missed cases annually. The
authors make the point that the risk of a false negative
from biotin assay interference is lower than the risks
involved with rapid rule out strategies. These have an
estimated misdiagnosis rate of ∼0.5% [20], which is
deemed clinically acceptable. This is a valid point and it is
reassuring that the number of cases missed may well be
small. It is also the case that rapid rule out protocols will
become the norm hence there is only a single sample on
admission and repeat sampling with physiological biotin
fall will not apply. Although strategies have been sug-
gested to mitigate risk in practice this will be difficult to
implement in the context of rapid diagnostic strategies
[21, 22].
Biotin interference remains an avoidable cause of false
negative results. In medicine risks are frequently additive
and often multiplicative. And in clinical medicine, Mur-
phy’s law applies with depressing frequency. It is therefore
encouraging that a more recent formulation of the cardiac
troponin T assay with a much higher biotin interference
threshold has been produced.
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